Sotevtamab  (Synonyms: 16B5; AB-16B5)

Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research^[1][2][3].

Sotevtamab inhibits the invasion of PANC-1 pancreatic cancer cells^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Sotevtamab (10 and 50 mg/kg, i.v.) is well tolerated and shows no signs of toxicity in monkeys^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2411526-47-9

[Sotevtamab]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gilles Tremblay, et al. Abstract 1467: AB-16B5, a therapeutic monoclonal antibody against human clusterin that blocks the epithelial-to-mesenchymal transition. Cancer Res 15 April 2010; 70 (8_Supplement): 1467.

  [2]. Cristiano Ferrario, et al. Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies. Cancer Res 1 July 2017; 77 (13_Supplement): CT098.

  [3]. Gilles B. et al. Pre-clinical evaluation of AB-16B5, a monoclonal antibody specific for tumor-associated sCLU, demonstrates therapeutic potential as an inhibitor of EMT in prostate, pancreatic and lung cancer. Cancer Res 15 April 2011; 71 (8_Supplement): LB–33.